Page last updated: 2024-12-07

2-(n,n-dipropyl)amino-5,6-dihydroxytetralin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(N,N-dipropyl)amino-5,6-dihydroxytetralin: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122167
CHEMBL ID11845
SCHEMBL ID7362530
MeSH IDM0065395

Synonyms (24)

Synonym
6-(dipropylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol
PDSP1_000012
PDSP2_001353
PDSP2_000012
PDSP1_000170
PDSP1_001369
PDSP2_000169
tl 102 (pharmaceutical)
CHEMBL11845 ,
64309-39-3
(+/-)-6-dipropylamino-5,6,7,8-tetrahydro-naphthalene-1,2-diol
bdbm50026553
(+)-6-dipropylamino-5,6,7,8-tetrahydro-naphthalene-1,2-diol
(-)-6-dipropylamino-5,6,7,8-tetrahydro-naphthalene-1,2-diol
6-dipropylamino-5,6,7,8-tetrahydro-naphthalene-1,2-diol (dp-5,6-adtn)
6-dipropylamino-5,6,7,8-tetrahydro-naphthalene-1,2-diol
A835385
5,6-dihydroxy-2-n,n-dipropylaminotetralin
n,n-dipropyl-5,6-adtn
2-(n,n-dipropyl)amino-5,6-dihydroxytetralin
1,2-naphthalenediol, 6-(dipropylamino)-5,6,7,8-tetrahydro-
SCHEMBL7362530
FT-0711849
DTXSID90982861

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Bromocriptine did not show this effect, as the dose-response relationships for HVA decrease, for induction of stereotypy and for the decrease in specific (-)DP-5,6-ADTN binding were all virtually equal to each other."( S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.
Feenstra, MG; Grol, CJ; Lewis, MH; Mailman, RB; Rollema, H; Staples, L, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorHomo sapiens (human)Ki0.21700.00000.651810.0000AID65888
DRattus norvegicus (Norway rat)IC50 (µMol)0.13550.00030.50267.7625AID62869; AID62870
DRattus norvegicus (Norway rat)Ki0.17000.00010.610010.0000AID61525
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.13550.00030.39075.4000AID62869; AID62870
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.13550.00030.35635.4000AID62869; AID62870
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.13550.00030.38715.4000AID62869; AID62870
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.13550.00010.54948.4000AID62869; AID62870
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.00300.00000.437510.0000AID65732
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorHomo sapiens (human)EC50 (µMol)0.00070.00000.18743.9000AID62759
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (97)

Processvia Protein(s)Taxonomy
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID191780In vivo dopaminergic activity was assessed by scoring stereotyped behavior in rats at dose 0.5 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID177646Effect on dopamine accumulation in striatum of rat.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
AID173658In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (HVA) levels in rat brain at dose 0.25 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID173659In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (HVA) levels in rat brain at dose 0.5 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID173656In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (DOPAC) levels in rat brain at dose 10 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID173650In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (DA) levels in rat brain at dose 0.25 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID177497Effect on 5-HTP accumulation in hemispheres of rat; Inactive1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
AID230026Ratio of Km to that Vmax in crude rat liver microsomes was determined1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
AID62759Tested for intrinsic activity towards Dopamine receptor D2 in CHO cells2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Orally active oxime derivatives of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one. Synthesis and pharmacological activity.
AID191781In vivo dopaminergic activity was assessed by scoring stereotyped behavior in rats at dose 10 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID184698post-synaptic effect was assayed by the increase in locomotor activity (reserpine pretreatment), at 0.25 umol/kg1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
AID224176D2-like activity was evaluated as pD2 on a superfused rabbit ear artery2000Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
Synthesis and dopaminergic activity of heterocyclic analogues of 5,6-dihydroxy-2-aminotetralins.
AID173655In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (DOPAC) levels in rat brain at dose 0.5 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID173657In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (DOPAC) levels in rat brain at dose 5 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID61525In vitro binding affinity towards Dopamine receptor D12003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Orally active oxime derivatives of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one. Synthesis and pharmacological activity.
AID177635Effect on 5-HTP accumulation in limbic system of rat; Inactive1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
AID173652In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (DA) levels in rat brain at dose 10 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID169649Compound is tested for its ability to displace (Di-Pr-5,6-ADTN) at 0.25 umol/kg of subcutaneous dose from rat striatal binding sites in vivo1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID197169Hypertensive activity (increase in arterial pressure to 60 mmHg)) after i.v. administration to pithed rats.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID185004Compound is tested for concomitant ability to antagonize the locomotor activity induced by Di-Pr-5,6-ADTN1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID173651In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (DA) levels in rat brain at dose 0.5 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID224175D1-like activity was evaluated as pD2 on a superfused rabbit splenic artery2000Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6
Synthesis and dopaminergic activity of heterocyclic analogues of 5,6-dihydroxy-2-aminotetralins.
AID63342Tested for percent intrinsic activity towards Dopamine receptor D1 in SK-N-MC cells2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Orally active oxime derivatives of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one. Synthesis and pharmacological activity.
AID191779In vivo dopaminergic activity was assessed by scoring stereotyped behavior in rats at dose 0.25 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID191782In vivo dopaminergic activity was assessed by scoring stereotyped behavior in rats at dose 5 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID173660In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (HVA) levels in rat brain at dose 10 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID173653In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (DA) levels in rat brain at dose 5 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID3678350% inhibition of specific [3H]clonidine binding (0.4 nM) to Alpha-2 adrenergic receptors in rat isolated brain membranes1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID177643Effect on dopamine accumulation in hemispheres of rat; Inactive1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
AID177644Effect on dopamine accumulation in limbic system of rat.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
AID173654In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (DOPAC) levels in rat brain at dose 0.25 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID62897Tested for percent intrinsic activity towards Dopamine receptor D2 in CHO cells2003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Orally active oxime derivatives of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one. Synthesis and pharmacological activity.
AID36715Binding affinity against alpha-1 adrenergic receptor is the ability to inhibit the specific [3H]prazosin binding (0.4 nM) to rat isolated brain membranes by 50% was reported.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID62869Inhibitory activity against [3H]NPA binding (0.45) to dopamine receptor in striata of female wistar rats1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID184432Apparent kinetic constant(Km) for the O-Methylation on crude rat liver microsomes.1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
AID191871Apparent kinetic constant(Vmax) for the O-Methylation on crude rat liver microsomes at 1 mg of protein1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
AID173661In vivo dopaminergic activity was assessed by measuring the decrease of DA metabolite (HVA) levels in rat brain at dose 5 umol/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
AID177637Effect on 5-HTP accumulation in striatum of rat; Inactive1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
AID65888Tested for affinity against cloned mammalian dopamine autoreceptor (DA) D2 receptors expressed in CHO-K1 cells using [3H]spiperone as radioligand1994Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17
Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.
AID65732In vitro binding affinity towards Dopamine receptor D22003Journal of medicinal chemistry, Sep-11, Volume: 46, Issue:19
Orally active oxime derivatives of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one. Synthesis and pharmacological activity.
AID62870Inhibitory activity against [3H]NPA binding (0.45) to dopamine receptors in striata of female wistar rats1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (86.11)18.7374
1990's2 (5.56)18.2507
2000's3 (8.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.44 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]